Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1195 participants.
Also called NCT03888066
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 1,195 participants
- Sponsor
- Registry
-
NCT03888066 -
2018-005030-38
-
- Other papers using this trial's data
- Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia: DIAMOND Subanalysis
- Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial
- Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Czechia, France, Georgia, Germany, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Russia, Serbia, Spain, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03888066. Randomized; quadruple masking; primary purpose prevention. Start 2019-04-24 (actual); primary completion 2021-09-02 (actual). Results posted on 2023-02-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
- Acronym
- DIAMOND
- Condition
- Hyperkalemia
- Intervention (Drug)
- Patiromer
- Intervention (Drug)
- Placebos
- Lead sponsor
- Vifor Pharma, Inc.
- Collaborator
- Syneos Health
Record details
- Record id
cardio:ct-nct03888066- Content hash
6f9c79fede9396559aa365dd3cc72e163dc9dc500f4f50b606a7d06ddea1a3e6